Seminars in thrombosis and hemostasis最新文献_第8页

Stress and Pregnancy Outcomes: A Review of the Literature. 压力与妊娠结果：文献综述。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2024-11-04 DOI: 10.1055/s-0044-1792002

Shayna Miodownik, Eyal Sheiner

引用次数: 0

Evaluating Diagnostic Algorithms for Heparin-Induced Thrombocytopenia using Two Combined Automated Rapid Immunoassays. 使用两种组合式自动快速免疫测定评估肝素诱发血小板减少症的诊断算法。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2024-11-01 Epub Date: 2024-05-11 DOI: 10.1055/s-0044-1786749

Anna-Lise Bissola, Yi Zhang, Madison Cranstone, Jane C Moore, Theodore E Warkentin, Donald M Arnold, Ishac Nazy

{"title":"Evaluating Diagnostic Algorithms for Heparin-Induced Thrombocytopenia using Two Combined Automated Rapid Immunoassays.","authors":"Anna-Lise Bissola, Yi Zhang, Madison Cranstone, Jane C Moore, Theodore E Warkentin, Donald M Arnold, Ishac Nazy","doi":"10.1055/s-0044-1786749","DOIUrl":"10.1055/s-0044-1786749","url":null,"abstract":"Heparin-induced thrombocytopenia (HIT) is an autoimmune disorder caused by antibodies against platelet factor 4 (PF4) and heparin complexes. Rapid immunoassays (IAs) for detection of these antibodies mark a milestone in HIT diagnosis, despite a higher false-positive rate compared with functional platelet-activation assays. However, combining different rapid IAs may help to improve their diagnostic specificity. Here, we compared the individual performance of the latex immunoturbidimetric assay (LIA; HemosIL HIT-Ab [PF4-H]; sensitivity 91.7%, specificity 68.4%) and chemiluminescence immunoassay (CLIA; HemosIL AcuStarHIT-Ab [PF4-H]; sensitivity 92.4%, specificity 85.8%) with their combined performance using two unique diagnostic algorithms in a single prospective cohort of suspected HIT patients. Using the simultaneous algorithm adapted from Warkentin et al, the combined LIA-CLIA had a sensitivity of 99.0% and specificity of 64.3%. The sequential algorithm adapted from Rittener-Ruff et al was applied in two theoretical scenarios to reflect real-world circumstances in diagnostic laboratories where access to clinical information is limited: (1) assuming all patients had an intermediate 4Ts score and (2) assuming all patients had a high 4Ts score. This algorithm correctly predicted HIT in 94.5% (high 4Ts) and 96.0% (intermediate 4Ts) and excluded HIT in 82.6% (high 4Ts) and 80.1% (intermediate 4Ts) of patients in either scenario, respectively. Although both combined algorithms improved diagnostic performance of individual IAs, the simultaneous algorithm showed fewer false predictions (7.9%) than the sequential algorithm (intermediate 4Ts: 37.6% and high 4Ts: 41.5%) and proved more practical as it does not rely on physician evaluations. Our findings highlight the importance of accounting for clinician and interlaboratory variability when evaluating diagnostic tests for HIT.","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":"1123-1130"},"PeriodicalIF":3.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140909361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pearls and Pitfalls in the Measurement of Direct Oral Anticoagulants. 直接口服抗凝血剂的测量要点和误区。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2024-11-01 Epub Date: 2024-03-08 DOI: 10.1055/s-0044-1782196

Giuseppe Lippi, Emmanuel J Favaloro

{"title":"Pearls and Pitfalls in the Measurement of Direct Oral Anticoagulants.","authors":"Giuseppe Lippi, Emmanuel J Favaloro","doi":"10.1055/s-0044-1782196","DOIUrl":"10.1055/s-0044-1782196","url":null,"abstract":"Due to their widespread use, testing for direct oral anticoagulants (DOACs) has become urgent in certain clinical situations. Screening based on widely available, rapid, and simple hemostasis assays such as prothrombin time, activated partial thromboplastin time, or even diluted Russel Viper venom time may provide sufficient evidence of \"over-coagulation\" and could be used \"in small/peripheral/spoke laboratories\" as an emergency strategy, but is not thought to be reliable for driving clinical decision making. Given their good correlation with plasma concentration, urine dipsticks may be considered a valuable alternative for emergency screening, although their performance is dependent on renal function, may vary depending on the time since the last urination, and there may be problems of interfacing with the laboratory/hospital information system. Separation methods based on liquid chromatography and mass spectrometry may be clinically questionable, since they measure the concentration rather than the actual inhibitory effect of DOACs, are relatively expensive, cumbersome and time consuming, and therefore seem unsuitable for most conditions requiring urgent clinical decision making. A proposed approach therefore involves establishing a network of routine clinical laboratories, designating a reference center where DOAC tests could be available 24/7, establishing a clear diagnostic care pathway for ordering the tests from the laboratory and standard operating procedures for performing them, the use of the diluted thrombin time for dabigatran and anti-FXa assays (drug-calibrated) for rivaroxaban, apixaban, and edoxaban, as well as providing expert advice throughout the testing process, from ordering to interpretation of results.","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":"1114-1122"},"PeriodicalIF":3.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140065853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Variable Performance of Lupus Anticoagulant Testing: The Australasian/Asia-Pacific Experience. 狼疮抗凝血测试的可变性能:澳大利亚/亚太经验。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2024-11-01 Epub Date: 2023-11-15 DOI: 10.1055/s-0043-1776406

Emmanuel J Favaloro, Elysse Dean, Sandya Arunachalam

{"title":"Variable Performance of Lupus Anticoagulant Testing: The Australasian/Asia-Pacific Experience.","authors":"Emmanuel J Favaloro, Elysse Dean, Sandya Arunachalam","doi":"10.1055/s-0043-1776406","DOIUrl":"10.1055/s-0043-1776406","url":null,"abstract":"Lupus anticoagulant (LA) is one of three tests identified as laboratory criteria for definite antiphospholipid syndrome (APS). The other two tests are anticardiolipin antibody (aCL) and anti-β2-glycoprotein I (aβ2GPI) antibody. The presence of LA is assessed using clot-based tests, while the presence of aCL and aβ2GPI is assessed by immunological assays. Since no test can be considered 100% sensitive or specific for LA, current guidelines recommend using two different clot-based assays reflecting different principles, with the dilute Russell viper venom time (dRVVT) and activated partial thromboplastin time (aPTT) recommended. Initially, LA-sensitive reagents are used to screen for LA, and then, in \"screen-positive\" samples, LA-\"insensitive\" reagents are used to confirm LA. Because LA assays are based on clot detection, anything that can interfere with fibrin clot development may affect test results. In particular, in addition to LA, the tests are also sensitive to the presence of a wide range of clinical anticoagulants, reflecting preanalytical issues for testing. We provide updated findings for LA testing in our geographic region, using recent data from the Royal College of Pathologists of Australasia Quality Assurance Programs, an international external quality assessment program with approximately 120 participants. Data show a wide variety of assays in use, especially for aPTT testing, and variable outcomes in reported numerical values with these assays when assessing proficiency samples. dRVVT testing mostly comprised reagents from three main manufacturing suppliers, which also showed differences in numerical values for the same homogeneous tested samples. Nevertheless, despite the use of different test reagents and processes, >98% of participants correctly identified LA-negative samples as LA-negative and LA-positive samples as LA positive. We hope our findings, reflecting on the heterogeneity of test processes and test data, help improve diagnostic testing for LA in the future.","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":"1103-1113"},"PeriodicalIF":3.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134649719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Internal Quality Control in Hemostasis Assays. 止血试验的内部质量控制。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2024-11-01 Epub Date: 2023-09-25 DOI: 10.1055/s-0043-1774381

Christopher Reilly-Stitt, Ian Jennings, Steve Kitchen, Isobel D Walker

{"title":"Internal Quality Control in Hemostasis Assays.","authors":"Christopher Reilly-Stitt, Ian Jennings, Steve Kitchen, Isobel D Walker","doi":"10.1055/s-0043-1774381","DOIUrl":"10.1055/s-0043-1774381","url":null,"abstract":"Internal quality control (IQC) for routine and specialist hemostasis testing represents a mandatory requirement for assays offered by clinical laboratories under International Organization for Standardization, Code of Federal Regulations, and Clinical and Laboratory Standards Institute standards. The underlying principle is that regular IQC audits the analytical performance of automated, semiautomated, and manual methods. This review investigates IQC practices, including benefits, limitations, frequency per time period or batch, sources of material used, primary supplier, third party or in-house, plus troubleshooting when IQC falls outside acceptance criteria. To assess IQC practice, the UK National External Quality Assessment Scheme (NEQAS) Blood Coagulation distributed a questionnaire to 1,200 participants enrolled in our scheme that collected details of the local practices for IQC testing. We received returns from 127 centers that described their local practices for the frequency of IQC, the type of IQC material employed, acceptance criteria for IQC data, and troubleshooting protocols for IQC failures. The data collected as part of an NEQAS BC questionnaire confirmed that all the participants returning answers to the questionnaire meet the standards for regular IQC testing for the hemostasis assays they perform.","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":"1084-1090"},"PeriodicalIF":3.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41169967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Strategies for Performing Factor Assays in the Presence of Emicizumab or Other Novel/Emerging Hemostatic Agents. 在使用埃米珠单抗或其他新型/新兴止血剂的情况下进行因子检测的策略。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2024-11-01 Epub Date: 2024-06-12 DOI: 10.1055/s-0044-1787189

Geoffrey Kershaw

{"title":"Strategies for Performing Factor Assays in the Presence of Emicizumab or Other Novel/Emerging Hemostatic Agents.","authors":"Geoffrey Kershaw","doi":"10.1055/s-0044-1787189","DOIUrl":"10.1055/s-0044-1787189","url":null,"abstract":"For several decades, therapeutic options for inherited deficiencies of factor VIII or IX (hemophilia A or B, respectively) have largely been the replacement of the missing clotting factor with plasma-derived or recombinant products. Hemostasis laboratories use standard activated partial thromboplastin time (aPTT)-based clotting or chromogenic assays to monitor plasma factor levels to guide therapy. The emergence in the past 10 years of extended half-life replacement products and other novel therapies for hemophilia has led to a reappraisal of assay suitability, with studies of product measurement showing some existing assay types or reagents to be unsuitable for some products. The hemostasis laboratory must adapt to the changing landscape by adding new assays or modifying existing assays to ensure accurate results for product measurement. These strategies include switching from a chromogenic assay to a clotting assay, or vice versa, changing an aPTT reagent brand, or introducing product specific calibrators. This article evaluates the effects of some of the newer treatment options on the laboratory testing of factor levels and related assays.","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":"1163-1172"},"PeriodicalIF":3.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141311572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Thrombophilia Screening: Not So Straightforward. 血栓性疾病筛查：没那么简单

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2024-11-01 Epub Date: 2024-05-11 DOI: 10.1055/s-0044-1786807

Gary W Moore

{"title":"Thrombophilia Screening: Not So Straightforward.","authors":"Gary W Moore","doi":"10.1055/s-0044-1786807","DOIUrl":"10.1055/s-0044-1786807","url":null,"abstract":"Although inherited thrombophilias are lifelong risk factors for a first thrombotic episode, progression to thrombosis is multifactorial and not all individuals with inherited thrombophilia develop thrombosis in their lifetimes. Consequently, indiscriminate screening in patients with idiopathic thrombosis is not recommended, since presence of a thrombophilia does not necessarily predict recurrence or influence management, and testing should be selective. It follows that a decision to undertake laboratory detection of thrombophilia should be aligned with a concerted effort to identify any significant abnormalities, because it will inform patient management. Deficiencies of antithrombin and protein C are rare and usually determined using phenotypic assays assessing biological activities, whereas protein S deficiency (also rare) is commonly detected with antigenic assays for the free form of protein S since available activity assays are considered to lack specificity. In each case, no single phenotypic assay is capable of detecting every deficiency, because the various mutations express different molecular characteristics, rendering thrombophilia screening repertoires employing one assay per potential deficiency, of limited effectiveness. Activated protein C resistance (APCR) is more common than discrete deficiencies of antithrombin, protein C, and protein S and also often detected initially with phenotypic assays; however, some centres perform only genetic analysis for factor V Leiden, as this is responsible for most cases of hereditary APCR, accepting that acquired APCR and rare F5 mutations conferring APCR will go undetected if only factor V Leiden is evaluated. All phenotypic assays have interferences and limitations, which must be factored into decisions about if, and when, to test, and be given consideration in the laboratory during assay performance and interpretation. This review looks in detail at performance and limitations of routine phenotypic thrombophilia assays.","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":"1131-1152"},"PeriodicalIF":3.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140907880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

International Council for Standardization in Haematology Guidance for New Lot Verification of Coagulation Reagents, Calibrators, and Controls. 国际血液学标准化委员会凝固试剂、校准器和对照品新批号验证指南。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2024-11-01 Epub Date: 2023-11-15 DOI: 10.1055/s-0043-1776405

Robert C Gosselin, Donna Castellone, Akbar Dorgalaleh, Kieron Hickey, Giuseppe Lippi, Karen Moffat, Rebecca O'Toole, Joe Rigano

引用次数: 0

Erratum: Laboratory Diagnosis of Activated Protein C Resistance and Factor V Leiden. 勘误表：活性蛋白C抗性和因子V莱顿的实验室诊断。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2024-11-01 Epub Date: 2023-10-25 DOI: 10.1055/s-0043-1776324

Mehran Bahraini, Alieh Fazeli, Akbar Dorgalaleh

引用次数: 0

New STH 2023 Impact Factor, Most Highly Cited Papers, and Other Journal Metrics. 新 STH 2023 影响因子、高被引论文及其他期刊指标。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2024-11-01 Epub Date: 2024-07-19 DOI: 10.1055/s-0044-1788566

Emmanuel J Favaloro

引用次数: 0